Development of potent CPP6–gemcitabine conjugates against human prostate cancer cell line (PC-3)
- 10 January 2020
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 11 (2) , 268-273
Abstract
Gemcitabine conjugation with CPP6 significantly enhanced cell growth inhibitory activity on PC-3 cells, with IC50 between 14 and 15 nM.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (SFRH/BD/140734/2018, PD/BD/135120/2017, SFRH/BPD/122871/2016, IF/00092/2014/CP1255/CT0004)
- European Regional Development Fund (IF/00092/2014/CP1255/CT0004)
This publication has 44 references indexed in Scilit:
- Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical ModificationsMolecular Pharmaceutics, 2012
- Applications of Cell-Penetrating Peptides for Tumor Targeting and Future Cancer TherapiesPharmaceuticals, 2012
- Cell-Penetrating Penta-Peptides (CPP5s): Measurement of Cell Entry and Protein-Transduction ActivityPharmaceuticals, 2010
- Identification of Novel Bioactive Hexapeptides Against Phytopathogenic Bacteria Through Rapid Screening of a Synthetic Combinatorial LibraryJournal of Microbiology and Biotechnology, 2009
- Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?British Journal of Cancer, 2007
- Cation−π Interactions Stabilize the Structure of the Antimicrobial Peptide Indolicidin near Membranes: Molecular Dynamics SimulationsThe Journal of Physical Chemistry B, 2006
- Sulforhodamine B colorimetric assay for cytotoxicity screeningNature Protocols, 2006
- The Preference of Tryptophan for Membrane InterfacesBiochemistry, 1998
- Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cellsThe Prostate, 1996
- CONFORMATIONS OF PROLINE‐CONTAINING CYCLIC PEPTIDES:International Journal of Peptide and Protein Research, 1977